The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)—First experimental arm (EA) initial results.
Thomas J. George
Consulting or Advisory Role - Bayer/Onyx; Merck
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); Pharmacyclics (Inst); Seattle Genetics (Inst); Tesaro (Inst)
Greg Yothers
Employment - Mountainview Pediatrics (I)
Consulting or Advisory Role - Orbus Therapeutics; Pharmacyclics
Theodore S. Hong
Consulting or Advisory Role - Clinical Genomics; EMD Serono
Research Funding - AstraZeneca (Inst); clinical genomics (Inst); Novartis (Inst); Taiho Pharmaceutical (Inst)
Marcia McGory Russell
No Relationships to Disclose
Y. Nancy You
No Relationships to Disclose
William Parker
No Relationships to Disclose
Samuel A. Jacobs
No Relationships to Disclose
Peter C. Lucas
Stock and Other Ownership Interests - Amgen
Consulting or Advisory Role - Bayer/Loxo (I)
Marc Jeffrey Gollub
Stock and Other Ownership Interests - Ariad Phrmaceuticals; G1 Therapeutics; Juno Therapeutics
William Adrian Hall
No Relationships to Disclose
Lisa A. Kachnic
Consulting or Advisory Role - INSYS Therapeautics; TRM Oncology
Patents, Royalties, Other Intellectual Property - UpToDate
Namrata Vijayvergia
Consulting or Advisory Role - Novartis
Research Funding - Merck (Inst)
Norman Wolmark
Research Funding - AstraZeneca/MedImmune (Inst)